90: Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth
V,
Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis
BL, Vaughn
DW.
Safety, immunogenicity, and protective efficacy
of NYVAC-JEV and
ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys.
Am J Trop Med Hyg. 1999 Mar;60(3):343-9.
89: Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth
V,
Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis
BL, Vaughn
DW.
An intranasal challenge model for testing
Japanese encephalitis vaccines
in rhesus monkeys.
Am J Trop Med Hyg. 1999 Mar;60(3):329-37.
88: Defraites RF, Gambel JM, Hoke CH Jr, Sanchez JL,
Withers BG,
Karabatsos N, Shope RE, Tirrell S, Yoshida I, Takagi
M,
Meschievitz CK, Tsai TF.
Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers:
immunogenicity and safety of vaccine administered in two dosing regimens.
Am J Trop Med Hyg. 1999 Aug;61(2):288-93.
87: Rojanasuphot S, Shaffer N, Chotpitayasunondh T,
Phumiamorn S,
Mock P, Chearskul S, Waranawat N, Yuentrakul P, Mastro
TD, Tsai
TF.
Response to JE vaccine among HIV-infected
children, Bangkok, Thailand.
Southeast Asian J Trop Med Public Health. 1998 Sep;29(3):443-50.
86: Wu YC, Huang YS, Chien LJ, Lin TL, Yueh YY, Tseng
WL, Chang
KJ, Wang GR.
The epidemiology of Japanese encephalitis
on Taiwan during 1966-1997.
Am J Trop Med Hyg. 1999 Jul;61(1):78-84.
85: Sohn YM, Park MS, Rho HO, Chandler LJ, Shope RE,
Tsai
TF.
Primary and booster immune responses to SA14-14-2
Japanese encephalitis
vaccine in Korean infants.
Vaccine. 1999 May 4;17(18):2259-64.
84: Konishi E, Yamaoka M, Khin-Sane-Win, Kurane I,
Takada K, Mason
PW.
The anamnestic neutralizing antibody response is critical for protection
of mice from challenge following vaccination with a plasmid encoding the
Japanese encephalitis virus premembrane and envelope genes.
J Virol. 1999 Jul;73(7):5527-34.
83: Guirakhoo F, Zhang ZX, Chambers TJ, Delagrave
S, Arroyo J,
Barrett AD, Monath TP.
Immunogenicity, genetic stability, and protective efficacy of a
recombinant, chimeric yellow fever-Japanese encephalitis virus
(ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese
encephalitis.
Virology. 1999 May 10;257(2):363-72.
82:
Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave
S,
Myers G, Barrett AD, Shope RE, Ratterree M, Chambers TJ,
Guirakhoo
F.
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax)
incorporating the envelope genes of Japanese encephalitis (SA14-14-2)
virus and the capsid and nonstructural genes of yellow fever (17D) virus
is safe, immunogenic and protective in non-human primates.
Vaccine. 1999 Apr 9;17(15-16):1869-82.
81: Matsunaga Y, Yabe S, Taniguchi K, Nakayama M, Kurane I.
[Current status of Japanese encephalitis in
Japan].
Kansenshogaku Zasshi. 1999 Feb;73(2):97-103. Japanese.